Abstract
Over the past decade, chikungunya virus (CHIKV)has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Réunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.
| Original language | English (US) |
|---|---|
| Journal | Vaccine |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Adenovirus
- Chikungunya
- Oral
- Tablet
- Vaccine
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- veterinary(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Cite this
An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling. / Dora, Emery G.; Rossi, Shannan; Weaver, Scott; Tucker, Sean N.; Mateo, Roberto.
In: Vaccine, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling
AU - Dora, Emery G.
AU - Rossi, Shannan
AU - Weaver, Scott
AU - Tucker, Sean N.
AU - Mateo, Roberto
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Over the past decade, chikungunya virus (CHIKV)has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Réunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.
AB - Over the past decade, chikungunya virus (CHIKV)has emerged as a major cause of mosquito-borne disease with transmission reported in over 100 countries worldwide. Although several strategies have been pursued for the development of a CHIKV vaccine, none has been approved yet. In this study, we describe the development of several vaccine vectors that express the structural proteins of the La Réunion CHIKV strain LR2006-OPY1. Protection from virus-induced pathologic changes was observed in vaccinated C57BL/6 mice, an important model for CHIKV vaccine development because of their ability to recapitulate several signs shown in infected humans. This study uniquely demonstrates the capacity of a mucosally-administered adenovirus vaccine to induce serum antibody responses and confer protective efficacy in a pre-clinical model. Our data provide further evidence in support of the clinical development of this oral Ad-CHIKV vaccine strategy in populations at high risk of contracting the disease.
KW - Adenovirus
KW - Chikungunya
KW - Oral
KW - Tablet
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85064836650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064836650&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2019.04.069
DO - 10.1016/j.vaccine.2019.04.069
M3 - Article
C2 - 31047675
AN - SCOPUS:85064836650
JO - Vaccine
JF - Vaccine
SN - 0264-410X
ER -